Spots Global Cancer Trial Database for Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Azacitidine Plus PD-1 Therapy for R/R Hodgkin Lymphoma
Official Title: Azacitidine Plus PD-1 Therapy for Relapsed/Refractory Hodgkin Lymphoma
Study ID: NCT06190067
Interventions
Study Description
Brief Summary: The goal of this phase 2 trial is to test the safety and efficacy of azacitidine when given together with PD-1 therapy in treating patients with relapsed/refractory classic Hodgkin lymphoma.
Detailed Description: The investigators will evaluate response rate, progression free survival (PFS), overall survival (OS), and toxicity of azacytidine combined with PD-1 therapy in classic relapsed/refractory Hodgkin lymphoma.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Navy General Hospital, Beijing, Beijing, China
Contact Details
Name: Liren Qian, PhD
Affiliation: Navy General Hospital, Beijing
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
